Scrip
1
00 Scrip’
S
anal
y
S
i
S
of the pharmaceutical indu
Melting…
is
is not
a
a novel
t
t
y….
y….
the
the environment makes
the
the difference!
Alpex Pharma is an independent Swiss drug delivery company specialised in the
Alpex Phardevelopment and manufacture of proprietary solid dosage forms such as ma is an independent Swiss drug delivery company specialized in the ODTdevelopment and
and manufactur
Effervescent
e of
T
pr
ablets
oprietar
. The predominant focus for
y solid dosage forms such
Alpex is the development
as Orally Disintegrating Tablets, Buccal
S
Tablets
of the solid dosage forms to deliver drugs directly into the oral cavity in order
and Effervescent Tablets. The predominant focus for Alpex is the development of solid dosage
tr
y’
forms to
S
to potentially improve the bioavailability of drugs and at the same time,
deliver drugs directly into the oral cavity in order to potentially improve the bioavailability of
performance and pro
drugs and
improve the patient compliance and convenience.
at the same time, improve the patient compliance and convenience.
The company
The company
, established
, established in 1985, has an effi
in 1985, was managed from
cient formulation development team
1992 by Elan Corporation as Elan Pharma
SA. It became
and a well experienced manufacturing site with an excellent cGMP
independent in 2004.
track record.
Alpex has
Alpex products are marketed worldwide and has a consistent pipe-line
an efficient formulation development team and a manufacturing site with an excellent
cGMP track
of new formulations for the European and the US market.
record.
S
pect
Alpex pr
Its state-of-the-art facility is conveniently located in the north of Lugano
oducts are marketed worldwide and has a consistent pipe-line of new formulations for the
European
and houses two independent dedicated plants for manufacturing and packaging
and the US market.
S
2009
Its state-of-the-ar
pharmaceutical and nutraceutical products.
t facility is conveniently located in north of Lugano and houses two independent
dedicated plants for pharmaceutical and nutraceutical products.
For mor
For more information, please contact:
e infor
A
mation,
lpe
please
x Pharma
contact:
Alpex Pharma SA
Alpex Phar
Via Cantonale,
ma
Fast r
SA
elease t
– Via Cantonale
echnology from Switzerland
CH-6805
CH-6805 Mezzovico (Lugano)
Mezzovico (Lugano), Switzerland
Tel: +41
Switzerland
(0) 91 935 51 10
Fax: +41
Tel
(0)
:
COMP
+4
91
1 (
935 ANY DESCRIPTION
0)91
51
93
20
5 51 10

r
No stirring required for tablet disintegration;
Email: contact@alpex.com
r
Sugar-free formula; and
Fax:
Alpex Pharma is a Swiss drug delivery company specialising
+41 (0)91 935 51 20

r
Safe for diabetics.
Website: Email: contact@alpex.comwww
in the formulation, development, r
.alpex.com
egistration and production
of solid dosage forms characterised by rapid release in water
Website: wwwor directly in the oral cavity.alpex.com. Alpex Pharma collaborates with
Granular in sachets containing moisture
large and medium-sized companies for the distribution of its
sensitive products
products in various markets.
Products can be formulated with the
following claims:
PRODUCTS/SERVICES
r
Administration at onset of symptoms;
t
Development capability – the company can carry out
r
Perceived faster onset;
compatibility studies on actives and excipients, formula-
r
Patient hydration: 150-200 ml of water required;
tion work including taste masking capability, analytical
r
Active ingredients (APIs) in suspension/solution;
development and validation, scale-up, stability studies,
r
Potential faster adsorption;
preparation of bio-batches, validation of manufacturing
r
Stirring required for tablet disintegration;
batches – all in GMP-compliant environments.
r
Sugar-free formula; and
r
Safe for diabetics.
t
Manufacturing of solid dosage forms – products
include orally disintegrating tablets (ODT), chewable
Orally Disintegrating Tablets
tablets, buccal tablets, effervescent tablets, effervescent
Tablets formulated according to this pat-
granular in sachets, granular in sachets and moisture-
ented proprietary technology are able to dis-
sensitive regular tablets.
solve rapidly on contact with saliva releasing
t
Packaging of products – moisture-proof packaging such
the drug from a highly soluble matrix.
as aluminium-aluminium blisters, aluminium-aluminium
Product features include:
strips, aluminium-aluminium sachets, plastic tubes and
plastic bottles with desiccant in the cap.
r
Sugar-free formula (safe for diabetics);
r
Highly hydrophilic matrix;
PRODUCT CHARACTERISTICS
r
Highly soluble matrix;
r
Suitable for those who dislike swallowing tablets,
Effervescent tablets and effervescent such as children and the elderly;
granular in sachets
r
Ideal for acute conditions; and
r
Can be used to treat migraine, allergies including hay
Effervescent products are characterised by a
fever, diarrhoea, gastro-oesophageal ref_lux disease, pain.
chemical incompatibility between a source of
CO2 (normally sodium bicarbonate) and an These products are also ideal for conditions in which
organic acid (e.g. citric, tartaric or malic acid). swallowing is compromised, including:
This is an autocatalytic reaction, catalysed
by the presence of water and heat, which
r
Emesis;
r
Parkinson’s disease; and
generates CO2 in solution:
r
Amyotrophic lateral sclerosis (ALS)/multiple sclerosis (MS).
H
2
O Buccal tablets
HCO
3
- + H CO
2

+
H
2
O
Tablets formulated according to this patented proprietary
(heat)
technology are able to dissolve in the oral
cavity releasing the drug to be absorbed through the buccal
The reaction is characterised by strict control of the residual mucosa. Product features include:
amount of moisture present in the ambient and produced
during the process, as well as on the f_inal dosage form. r
Sugar-free formula (safe for diabetics);
The advantages of an effervescent form can be
r
Highly hydrophilic matrix;
summarised as below:
r
Highly soluble matrix;
r
Drugs can be adsorbed avoiding stomach degradation;
r
Administration at onset of symptoms; and
r
Perceived faster onset; r
Ideal for acute conditions.
r
Patient hydration: 150-200 ml of water required;
r
Active ingredients (APIs) in suspension/solution (this can
result in better absorption); CONTACT INFORMATION
r
Buffered solution because of presence of CO2;
r
Protection of gastric mucosa;
Alpex Pharma SA Tel: +41 91 935 5110
r
Potential faster adsorption;
6805 Mezzovico Email: contact@alpex.com
r
Fizzy solution (taste improvement);
Switzerland Web: www.alpex.com
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128